Is there a role for combination therapy for osteoporosis?

Endocrine

Volumn 44, Issue 1, 2013, Pages 5-7

  Cosman, Felicia ^a  

^a HELEN HAYES HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; ANABOLIC AGENT; ANTIRESORPTIVE AGENT; BISPHOSPHONIC ACID DERIVATIVE; CARBOXY TERMINAL TELOPEPTIDE; PARATHYROID HORMONE; PARATHYROID HORMONE[1-34]; PROCOLLAGEN TYPE 3 AMINOPROPEPTIDE; RALOXIFENE; RISEDRONIC ACID; UNCLASSIFIED DRUG; ZOLEDRONIC ACID;

ADD ON THERAPY; BONE DENSITY; BONE MASS; BONE STRENGTH; DRUG EFFECT; DRUG MECHANISM; DRUG RESPONSE; DRUG WITHDRAWAL; EDITORIAL; HUMAN; MONOTHERAPY; OSTEOLYSIS; OSTEOPOROSIS; PARATHYROID FUNCTION; PRIORITY JOURNAL;

BONE DENSITY CONSERVATION AGENTS; ETIDRONIC ACID; HUMANS; MALE; OSTEOPOROSIS; TERIPARATIDE;

EID: 84881144012     PISSN: 1355008X     EISSN: 15590100     Source Type: Journal    
DOI: 10.1007/s12020-013-9954-6     Document Type: Editorial

References (15)

1. Walker, M.D., Cusano, N.E., Sliney, J., Jr., Romano, M., Zhang, C., McMahon, D.J., Bilezikian, J.P.: Combination therapy with risedronate and teriparatide in male osteoporosis. Endocrine (2012). doi: 10.1007/s12020-012- 9819-4
2. J. Compston, The use of combination therapy in the treatment of postmenopausal osteoporosis. Endocrine 41(1), 11-18 (2012). doi: 10.1007/s12020-011-9554-2
3. G. Mazziotti, J. Bilezikian, E. Canalis, D. Cocchi, A. Giustina, New understanding and treatments for osteoporosis. Endocrine 41(1), 58-69 (2012). doi: 10.1007/s12020-011-9570-2
4. B. Ettinger, J. San Martin, G. Crans, I. Pavo, Differential effects of teriparatide on BMD after treatment with raloxifene or alendronate. J. Bone Miner. Res. 19(5), 745-751 (2004). doi: 10.1359/JBMR.040117
5. P.D. Miller, P.D. Delmas, R. Lindsay, N.B. Watts, M. Luckey, J. Adachi, K. Saag, S.L. Greenspan, E. Seeman, S. Boonen, S. Meeves, T.F. Lang, J.P. Bilezikian, Early responsiveness of women with osteoporosis to teriparatide after therapy with alendronate or risedronate. J. Clin. Endocrinol. Metab. 93(10), 3785-3793 (2008). doi: 10.1210/jc.2008-0353
6. S. Boonen, F. Marin, B. Obermayer-Pietsch, M.E. Simoes, C. Barker, E.V. Glass, P. Hadji, G. Lyritis, H. Oertel, T. Nickelsen, E.V. McCloskey, Effects of previous antiresorptive therapy on the bone mineral density response to two years of teriparatide treatment in postmenopausal women with osteoporosis. J. Clin. Endocrinol. Metab. 93(3), 852-860 (2008)
7. F. Cosman, J. Nieves, M. Zion, L. Woelfert, M. Luckey, R. Lindsay, Daily and cyclic parathyroid hormone in women receiving alendronate. N. Engl. J. Med. 353(6), 566-575 (2005)
8. F. Cosman, R.A. Wermers, C. Recknor, K.F. Mauck, L. Xie, E.V. Glass, J.H. Krege, Effects of teriparatide in postmenopausal women with osteoporosis on prior alendronate or raloxifene: differences between stopping and continuing the antiresorptive agent. J. Clin. Endocrinol. Metab. 94(10), 3772-3780 (2009). doi: 10.1210/jc.2008-2719
9. Cosman, F., Keaveny, T.M., Kopperdahl, D., Wermers, R.A., Wan, X., Krohn, K.D., Krege, J.H.: Hip and spine strength effects of adding versus switching to teriparatide in postmenopausal women with osteoporosis treated with prior alendronate or raloxifene. J. Bone Miner. Res. n/a-n/a (2012). doi: 10.1002/jbmr.1853
10. D.M. Black, S.L. Greenspan, K.E. Ensrud, L. Palermo, J.A. McGowan, T.F. Lang, P. Garnero, M.L. Bouxsein, J.P. Bilezikian, C.J. Rosen, T.H.S.I. Pa, The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. N. Eng. J. Med. 349(13), 1207-1215 (2003). doi: 10.1056/NEJMoa031975
11. F. Cosman, E.F. Eriksen, C. Recknor, P.D. Miller, N. Guanabens, C. Kasperk, P. Papanastasiou, A. Readie, H. Rao, J.A. Gasser, C. Bucci-Rechtweg, S. Boonen, Effects of intravenous zoledronic acid plus subcutaneous teriparatide [rhPTH(1-34)] in postmenopausal osteoporosis. J. Bone Miner. Res. 26(3), 503-511 (2011). doi: 10.1002/jbmr.238
12. C. Deal, M. Omizo, E.N. Schwartz, E.F. Eriksen, P. Cantor, J. Wang, E.V. Glass, S.L. Myers, J.H. Krege, Combination teriparatide and raloxifene therapy for postmenopausal osteoporosis: results from a 6-month double-blind placebo-controlled trial. J. Bone Miner. Res. 20(11), 1905-1911 (2005). doi: 10.1359/JBMR.050714
13. C. Muschitz, R. Kocijan, A. Fahrleitner-Pammer, S. Lung, H. Resch, Antiresorptives overlapping ongoing teriparatide treatment result in additional increases in bone mineral density. J. Bone Miner. Res. 28(1), 196-205 (2013). doi: 10.1002/jbmr.1716
14. E.S. Orwoll, W.H. Scheele, S. Paul, S. Adami, U. Syversen, A. Diez-Perez, J.M. Kaufman, A.D. Clancy, G.A. Gaich, The effect of teriparatide [human parathyroid hormone (1-34)] therapy on bone density in men with osteoporosis. J. Bone Miner. Res. 18(1), 9-17 (2003). doi: 10.1359/jbmr.2003.18.1.9
15. R. Marcus, O. Wang, J. Satterwhite, B. Mitlak, The skeletal response to teriparatide is largely independent of age, initial bone mineral density, and prevalent vertebral fractures in postmenopausal women with osteoporosis. J. Bone Miner. Res. 18(1), 18-23 (2003). doi: 10.1359/jbmr.2003.18.1.18